Ocaliva (Obeticholic Acid)
- Medicine Name: Ocaliva
- Generic Name: Obeticholic Acid
- Dosage Form & Strength: Tablets: 5 mg, 10 mg
- Manufactured By: Intercept Pharmaceuticals, Inc.
Ocaliva is a farnesoid X receptor (FXR) agonist used in the treatment of adult patients with primary biliary cholangitis (PBC):
- without cirrhosis or
- with compensated cirrhosis who do not have evidence of portal hypertension,
- either in conjunction with ursodeoxycholic acid (UDCA) with an inadequate response to ursodeoxycholic acid or as monotherapy in those not able to tolerate ursodeoxycholic acid (UDCA).
Recommended Dosage: The recommended dose of Ocaliva tablet for primary biliary cholangitis patients without cirrhosis or with compensated cirrhosis who do not have known portal hypertension, who have not reached an apt biochemical response to an apt dosage of ursodeoxycholic acid for at least 12 months or are intolerant to ursodeoxycholic acid follows below:
- Start with an Ocaliva dosage of 5 mg once a day for the initial three months.
- Following the initial 3 months, for individuals who have not reached an appropriate reduction in ALP or total bilirubin and those who are tolerating the medicine Ocaliva, enhance to a maximum dosage of 10 mg once a day.
Take Ocaliva either with or without meal/food. For patients with bile acid binding resin, take Ocaliva 5mg or 10mg at least 4 hours prior to or 4 hours following the use of bile acid binding resin, or at as great an interval as possible.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.